Medicine for metastatic pancreatic cancer possibly on the Dutch market

Summary

The European Medicines Agency's committee recommends fast-tracking the drug Rasonque for market approval. Rasonque is intended for adults with metastatic pancreatic cancer who have already undergone treatment, aiming to slow cancer growth.